

REMARKS

The purpose of this Preliminary Amendment is to eliminate multiple dependent claims in order to avoid the additional fee. Applicants reserve the right to reintroduce claims to canceled combined subject matter.

Respectfully submitted,

\_\_\_\_\_  
Anthony J. Zelano, Reg. No. 27,969  
Attorney for Applicants  
MILLEN, WHITE, ZELANO & BRANIGAN, P.C.  
Arlington Courthouse Plaza 1  
2200 Clarendon Boulevard, Suite 1400  
Arlington, VA 22201  
Direct Dial: 703-812-5311  
Facsimile: 703-243-6410  
Email: zelano@mwzb.com

AJZ:jmm

09207401-041304

VERSION WITH MARKINGS TO SHOW CHANGES MADE

In the Specification:

A new first paragraph was inserted on page 1 of the specification. No marked up version is necessary.

In the Claims:

Claims 3, 4 and 6 have been amended as follows:

3. (Amended) Formulation according to ~~claims~~claim 1 ~~or 2~~ comprising a derivative of folic acid selected from the group consisting of 5-methyltetrahydrofolic acid, tetrahydrofolic acid, dihydrofolic acid, 5-formyltetrahydrofolic acid, 10-formyltetrahydrofolic acid, 5, 10-methylenetetrahydrofolic acid and 5-methenyltetrahydrofolic acid or their suitable salts.

5. (Amended) Formulation according to ~~claims~~claim 1 ~~to 4~~ in the form of a dosage unit, comprising 400 to 5000 mcg of dihydro- or tetrahydrofolic acid derivatives.

6. (Amended) Formulation according to ~~claims~~claim 1 ~~to 4~~ in the form of a dosage unit, comprising 400 to 5000 mcg of 5-formyltetrahydrofolic acid or its salts, 50 mg to 2000 mg of betaine anhydrous and 0.5 to 10 mcg of vitamin B12.

09807401 "044304  
T05T09 T04T08